JS105 + toripalimab + paclitaxel (albumin bound)

JS105 + toripalimab + paclitaxel (albumin bound) is a combination regimen consisting of JS105, toripalimab, and paclitaxel in its albumin-bound formulation (commonly referred to as nab-paclitaxel). Toripalimab is a humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1), acting as an immune checkpoint inhibitor. Paclitaxel (albumin bound) is a chemotherapeutic agent (taxane class) that stabilizes microtubules and inhibits cell mitosis. JS105 is a compound investigated in early-phase trials in combination with chemotherapeutics and immunotherapies for solid tumors, though its precise molecular identity and mechanism are not publicly detailed in the available sources. The combination is being studied for synergistic antitumor effects in solid tumors, including pancreatic ductal adenocarcinoma and advanced triple-negative breast cancer, leveraging immunomodulatory and cytotoxic mechanisms[1][3][4][5][8].

Brand names

LoqtorziAbraxane

Other names

JS105 + toripalimab + nab-paclitaxelJS105 + toripalimab + paclitaxel-albuminJS105 + toripalimab + albumin-bound paclitaxel